### Q1. Maria's GAD-7 score of 5 failed to detect her anxiety. Which factor most directly explains this screening failure? A) Instrument bias toward cognitive symptoms B) Insufficient overall test sensitivity C) Limited English language proficiency D) Genuinely subthreshold symptom severity E) Interviewer administration error **Correct: A** **ACGME: SBP | ABPN: D.V Diagnostic Assessments and Rating Scales** **Why A:** The GAD-7 was developed and validated primarily in English-speaking, non-Hispanic White populations. Its items emphasize cognitive worry symptoms ("feeling nervous," "worrying too much," "trouble relaxing") rather than the somatic presentations (headaches, chest sensations, stomach pain) that predominate in many culturally variant anxiety presentations (Hinton and Lewis-Fernandez, 2010, Depression and Anxiety). Measurement invariance studies show that specific GAD-7 items function differently across cultural groups, meaning identical scores may reflect different anxiety severity levels in different populations. Maria's anxiety is expressed through nervios, a culturally recognized syndrome of chronic nervousness, somatic distress, and emotional vulnerability that does not map directly onto GAD-7 items. The instrument's item structure, not its psychometric sensitivity in general, is the problem. **Why B is wrong:** The GAD-7 has well-established sensitivity (~89%) for generalized anxiety disorder in the populations where it was validated. The issue is not that the instrument poorly detects anxiety in general but that its item content is biased toward cognitive-verbal expression of worry, which may not capture anxiety expressed through somatic idioms. A sensitive instrument that asks the wrong questions still misses the presentation. **Why C is wrong:** Language barriers are a real access issue, but Maria's screening failure is not primarily a translation problem. Even a perfectly translated GAD-7 in Spanish would ask about "worrying too much" rather than headaches, chest shaking, or stomach pain. Back-translation ensures linguistic equivalence but does not guarantee conceptual equivalence across cultures. The screening miss is about construct coverage, not language. **Why D is wrong:** Maria has had persistent worry, insomnia, muscle tension, and social avoidance for two years, meeting DSM-5-TR criteria for GAD. Her symptom severity is not subthreshold; the instrument failed to capture it. Labeling her as subthreshold based on a culturally insensitive screening score would perpetuate the diagnostic error. **Why E is wrong:** The vignette describes standard instrument administration with no procedural irregularities. The bilingual social worker's subsequent open-ended interview successfully detected what the standardized instrument missed, confirming that the problem lies in the instrument's construct coverage, not the administration process. ---

### Q5. Based on Gerald's treatment history, does he meet criteria for treatment-resistant anxiety? A) No, he responded to clonazepam B) No, requires hospitalization history C) Yes, he meets both criteria D) Yes, only the pharmacotherapy criterion E) Cannot determine without HAM-A score **Correct: C** **ACGME: MK | ABPN: C.VI Prognosis and Course of Illness** **Why C:** The Domschke et al. Delphi consensus requires two criteria for treatment-resistant anxiety: (1) documented failure of multiple adequate first-line pharmacological trials across different classes, AND (2) documented failure of an adequate trial of evidence-based psychotherapy. Gerald satisfies both: he failed sertraline (SSRI), venlafaxine (SNRI), and buspirone (azapirone) at adequate doses for adequate durations, and he completed 16 sessions of CBT including exposure with insufficient response. His subsequent response to clonazepam does not retroactively disqualify the treatment resistance designation; it means he found a treatment that works after meeting resistance criteria. The distinction matters clinically: it provides the evidentiary justification for maintenance on a medication that would not be first-line in treatment-naive patients. (Domschke et al., 2024, World Psychiatry) **Why A is wrong:** Treatment resistance is defined by the pathway to treatment, not the current response. A patient who responded only to a fourth-line agent after failing three first-line interventions is treatment-resistant by definition, even though they are currently well-managed. This is analogous to calling a malignancy "treatment-resistant" when it responded to fourth-line chemotherapy: the response does not erase the resistance to earlier lines. **Why B is wrong:** The Domschke Delphi criteria do not include hospitalization. Treatment resistance is defined by failure of adequate trials across medication classes AND psychotherapy, not by service utilization. This is a fabricated criterion. **Why D is wrong:** Gerald meets BOTH criteria, not just one. He failed three first-line medications across two classes AND completed adequate CBT with insufficient response. The second criterion (psychotherapy failure) is essential: a patient who has tried three medications but never received evidence-based psychotherapy does not meet the Delphi threshold, regardless of how many pharmacological agents have been tried. **Why E is wrong:** The Domschke criteria do not require a specific symptom severity score. They require documented failure of adequate pharmacological and psychotherapeutic trials. Gerald's clinical history provides that documentation. Symptom rating scales are useful for tracking treatment response but are not gatekeeping criteria for the treatment resistance designation. ---

### Q10. Naveen asks about the evidence for ketamine specifically for anxiety disorders. Which statement most accurately reflects the current evidence? A) FDA-approved for anxiety disorders B) Strong Phase 3 trial support C) Preliminary signal from small trials D) No anxiolytic effects demonstrated E) Evidence equivalent to SSRIs **Correct: C** **ACGME: MK | ABPN: E.II Psychopharmacology Principles** **Why C:** The anxiety-specific ketamine evidence includes a transdiagnostic systematic review and meta-analysis (Hartland et al., 2023, Journal of Psychopharmacology) finding significant anxiolytic effects within 12 hours of a single dose, sustained for 1-2 weeks, across mood disorder, chronic pain, and palliative care settings. An open-label ascending-dose study (Glue et al., 2017, Journal of Psychopharmacology) found dose-related anxiolytic effects in 12 patients with treatment-resistant GAD and social anxiety, with a double-blind replication (Glue et al., 2020, Journal of Psychopharmacology) showing similar effects. However, total patient numbers in anxiety-specific trials remain small, most evidence comes from secondary outcomes in depression trials, and no anxiety-specific Phase 3 trial exists. This is a preliminary signal with mechanistic rationale, not clinical-grade evidence for routine use. **Why A is wrong:** Esketamine (Spravato) is FDA-approved for treatment-resistant depression only. No ketamine formulation has an FDA anxiety indication. The ketamine clinics Naveen is reading about offer off-label use, which is legal but not supported by the same evidence standard as an FDA-approved indication. **Why B is wrong:** No Phase 3 trial of ketamine for any primary anxiety disorder has been conducted. The available evidence comes from Phase 2 open-label studies, exploratory double-blind studies with small samples, and secondary anxiety outcomes in depression trials. "Strong Phase 3 support" would require large, multi-site, placebo-controlled trials with anxiety as the primary outcome. **Why D is wrong:** Anxiolytic effects have been demonstrated, both in meta-analytic data (Hartland 2023) and in small controlled studies (Glue 2017, 2020). The issue is not absence of signal but insufficient evidence for clinical recommendations. Dismissing the signal entirely would be inaccurate. **Why E is wrong:** No direct comparison trials between ketamine and SSRIs for anxiety exist. The SSRI evidence base includes hundreds of RCTs across multiple anxiety disorders with thousands of participants. The ketamine anxiety evidence comprises a handful of small studies. These evidence bases are not comparable in depth, breadth, or quality. ---

### Q14. Which characteristic of guided iCBT is most critical to its effectiveness compared to unguided programs? A) Brief weekly therapist feedback B) Multimedia content delivery system C) Unlimited program access D) Gamification elements E) Automated progress tracking **Correct: A** **ACGME: PC | ABPN: E.XII Psychotherapy** **Why A:** The distinction between guided and unguided iCBT is one of the most consistent findings in the digital therapeutics literature. Guided iCBT (where a therapist provides brief weekly feedback, typically 10-15 minutes per week) produces large effect sizes (d=0.80-1.0 vs inactive controls) and non-inferiority data relative to face-to-face CBT, while unguided programs show substantially lower effect sizes and critically higher dropout rates (Andersson et al., 2014, World Psychiatry; Andrews et al., 2018, Journal of Anxiety Disorders). The therapeutic relationship, even in its most reduced form (brief text or email check-ins), appears to be a necessary ingredient for most patients. This finding has direct scalability implications: guided iCBT is not a replacement for human involvement but a model that extends one therapist's capacity across many more patients. **Why B is wrong:** Multimedia elements (videos, animations, interactive exercises) can enhance engagement and accommodate different learning styles, but the evidence consistently identifies therapist contact, not content delivery method, as the critical variable distinguishing effective from ineffective iCBT. A beautifully designed unguided program still produces lower effects than a text-based program with weekly therapist check-ins. **Why C is wrong:** Unlimited access to program materials does not compensate for the absence of therapist guidance. Most iCBT programs provide time-limited structured modules (typically 6-12 weeks), and completion rates are determined more by therapeutic support than by access duration. Extending access without adding guidance does not improve outcomes. **Why D is wrong:** Gamification (points, badges, streaks) has been incorporated into some mental health apps to improve engagement, but no evidence identifies it as a critical effectiveness ingredient for clinical anxiety outcomes. Engagement and efficacy are related but not identical: a patient may use an app regularly without experiencing clinically meaningful symptom reduction. **Why E is wrong:** Automated progress tracking is a useful program feature that can alert both patient and therapist to changes in symptom trajectories, but it is a monitoring function, not a therapeutic mechanism. The tracking itself does not produce the therapeutic change; the human response to tracked data does. ---

### Q17. Which feature of Ava's presentation is most inconsistent with a GAD diagnosis? A) Her GAD-7 score of 11 B) Muscle tension and difficulty concentrating C) Worry about academic performance D) Sleep disruption during exams E) No functional impairment or avoidance **Correct: E** **ACGME: PC | ABPN: C.III Clinical Presentation, Symptoms, and Signs** **Why E:** The DSM-5-TR requirement that symptoms cause "significant distress or functional impairment" is the primary safeguard against overdiagnosis. Functional impairment means the patient is not doing something they would otherwise do: avoiding social situations, missing work, not sleeping, declining activities, or spending significant time managing symptoms rather than living. Ava does not avoid any activities. She maintains friendships, attends classes, exercises regularly, and describes her worry as manageable between exam periods. Her anxiety is contextual (exam-period worsening), time-limited, and non-avoidant, features more consistent with an adaptive stress response to legitimate academic pressure than a persistent clinical disorder. A patient who worries but functions fully is anxious; a patient who has reorganized their life around avoidance likely meets criteria for a disorder. (APA, 2022, DSM-5-TR) **Why A is wrong:** A GAD-7 score of 11 places Ava in the "moderate anxiety" range, above the screening cutoff of 10. However, the GAD-7 measures symptom severity at the time of administration and has known sensitivity to acute distress that may not represent a persistent disorder. A score during exam week may reflect transient stress rather than a persistent condition. The score triggers further evaluation, not a diagnosis. **Why B is wrong:** Muscle tension and difficulty concentrating are GAD symptoms, but they also occur in acute stress responses, sleep deprivation, and high-demand academic environments. The symptoms themselves do not distinguish pathological from adaptive anxiety; their persistence, generalization, and associated impairment do. Ava reports these symptoms worsen during exam periods, suggesting contextual activation rather than trait-level pathology. **Why C is wrong:** Worry about grades is appropriate for a pre-med student taking organic chemistry, particularly during exams. The DSM-5-TR proportionality criterion matters here: worry proportionate to a genuine stressor is adaptive, not pathological. GAD worry is excessive relative to the trigger, generalized beyond the triggering context, and difficult to control. Ava's worry is context-bound and manageable between exams. **Why D is wrong:** Sleeping 4-5 hours during exam periods is common among college students and likely reflects study habits and academic demands rather than anxiety-driven insomnia. Sleep disruption that persists after the stressor resolves would be more concerning. Ava's sleep pattern appears to be exam-specific, not chronic. ---

### Q20. Rosie's behavioral pattern is most consistent with which risk factor for later anxiety disorder development? A) Oppositional defiant disorder B) Autism spectrum disorder C) Speech-language disorder D) Reactive attachment disorder E) Behavioral inhibition **Correct: E** **ACGME: PC | ABPN: C.II Predisposing, Protective, and Risk Factors** **Why E:** Rosie's presentation, extreme shyness, withdrawal from unfamiliar people, refusal to speak outside the home, clinging behavior, and distress with novel social situations, is consistent with behavioral inhibition (BI), the strongest identified temperament-based risk factor for later anxiety disorders. Prospective data show BI confers an odds ratio of 7.59 for social anxiety disorder (Module 1). Rosie does not yet meet criteria for an anxiety disorder; her distress is limited to the school setting and her home functioning is typical. However, her temperamental pattern, combined with her mother's GAD history, places her in the highest-risk category for indicated prevention. The school psychologist is often the first professional to observe the "quiet child" who is easy to miss because they are compliant and non-disruptive. (Clauss & Blackford, 2012, JAACAP) **Why A is wrong:** Oppositional defiant disorder is characterized by angry/irritable mood, argumentative/defiant behavior, and vindictiveness. Rosie is not defiant or argumentative; she is withdrawn, anxious, and avoidant. The behavioral patterns are opposite: ODD involves approach-based conflict while BI involves withdrawal-based avoidance. **Why B is wrong:** Autism spectrum disorder can present with social difficulties and restricted behavior, but the key differentiator is that Rosie speaks normally at home and her social withdrawal is fear-based (cries at drop-off, clings to aide) rather than reflecting social communication deficits or restricted interests. Selective mutism with BI is fear-driven, while ASD-related social difficulties reflect neurodevelopmental differences in social communication. **Why C is wrong:** Rosie speaks normally at home, ruling out a primary speech-language disorder. Her school-based mutism reflects anxiety-driven inhibition, not a language production deficit. The context-dependence (speaks at home, silent at school) is the hallmark of selective mutism superimposed on behavioral inhibition. **Why D is wrong:** Reactive attachment disorder results from severe early neglect or abuse and is characterized by emotionally withdrawn behavior toward adult caregivers. Rosie has an appropriate attachment to her parents (speaks normally at home, clings to familiar adults). Her withdrawal is specific to unfamiliar social contexts, not a global attachment disruption. ---

### Q24. Travis asks about the clinical trial evidence for CBD in anxiety disorders. The existing studies have used doses of 150-600 mg, while commercial products typically contain 10-50 mg per dose. Which characterization of the evidence base is most accurate? A) Small, short-term, no large RCTs B) Large RCTs confirm GAD efficacy C) FDA-approved for anxiety D) Evidence equivalent to SSRIs E) No human studies exist **Correct: A** **ACGME: PC | ABPN: E.II Psychopharmacology Principles** **Why A:** CBD has limited, mixed clinical trial evidence for anxiety: a small number of studies using single-dose or short-course designs found modest anxiolytic effects in laboratory-induced anxiety paradigms and specific populations (social anxiety, PTSD-related sleep disturbance). Critically, the doses used in clinical studies (150-600 mg) far exceed those in commercial products (typically 10-50 mg per dose). No large, well-powered, placebo-controlled RCTs exist for any DSM-defined anxiety disorder with adequate follow-up duration. CBD is not FDA-approved for any anxiety indication. Epidiolex is FDA-approved only for specific seizure disorders. The clinical counseling task is validating Travis's interest while providing honest evidence-tier assessment. (Black et al., 2019, Lancet Psychiatry) **Why B is wrong:** No large RCTs confirm CBD efficacy for GAD or any other primary anxiety disorder. The available studies are small, mostly single-dose or short-term, and most tested laboratory-induced anxiety rather than clinical populations with DSM-defined disorders. "Large RCTs confirm efficacy" would require multi-site, adequately powered, placebo-controlled trials with anxiety as the primary outcome. **Why C is wrong:** CBD is not FDA-approved for any anxiety indication. Epidiolex (pharmaceutical-grade CBD) is FDA-approved only for specific seizure disorders (Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex). The widespread availability of hemp-derived CBD supplements does not constitute FDA approval for anxiety treatment. **Why D is wrong:** No direct comparison trials between CBD and SSRIs for anxiety exist. The SSRI evidence base includes hundreds of RCTs across multiple disorders; the CBD evidence comprises a handful of small studies. These evidence bases are not comparable in depth, breadth, or quality, and claiming equivalence misrepresents the state of the science. **Why E is wrong:** Human studies do exist: Bergamaschi et al. (2011, Neuropsychopharmacology) found CBD reduced anxiety in a simulated public speaking test in treatment-naive social phobia patients. Several other small studies have examined single-dose and short-course effects. The evidence is not absent; it is preliminary, small-scale, and insufficient to support clinical recommendations. ---